You are here: Industry Insights > Incyte

News List

Incyte agrees to licence three products to Innovent Biologics pharmaceutical-technology
December 19, 2018
US-based pharmaceutical company Incyte has signed a strategic collaboration agreement to out-licence three clinical-stage products to China-based Innovent Biologics.....
Innovent buys Chinese rights to Incyte drugs for $40M upfront fiercebiotech
December 18, 2018
Innovent Biologics has bagged the Chinese rights to three clinical-phase oncology and hematology drugs in development at Incyte.
Innovent and Incyte Announce Strategic Collaboration and Licensing Agreement for Three Clinical-stage Product Candidates in China pharmafocusasia
December 17, 2018
Innovent Biologics, Inc. and Incyte today announced that the companies, through their respective subsidiaries, have entered into a strategic collaboration agreement for .....
Incyte Announces CFO to Retire at End of 2018 americanpharmaceuticalreview
September 10, 2018
Incyte announced that David Gryska, Executive Vice President and Chief Financial Officer, intends to retire at the end of 2018 and that Incyte has launched a search for his replacement.
Incyte/MSD's immunotherapy combo fails in Phase III pharmatimes
July 17, 2018
A late stage trial testing Incyte’s epacadostat in combination with MSD’s Keytruda has failed to hit its primary targets in patients with unresectable or metastatic melanoma.
Incyte wipes out late-phase epacadostat program after pivotal failure of Keytruda combination fiercebiotech
May 02, 2018
Incyte has taken an ax to its suite of late-phase epacadostat trials after digesting the implications of last month’s pivotal study blowup.
Incyte/MSD's immunotherapy combo fails in Phase III pharmatimes
April 10, 2018
A late stage trial testing Incyte’s epacadostat in combination with MSD’s Keytruda has failed to hit its primary targets in patients with unresectable or metastatic melanoma.
Incyte and Merck Provide Update on Phase 3 Study of Epacadostat in Combination with KEYTRUDA® (pembrolizumab) in Patients with Unresectable or Metastatic Melanoma biospace
April 08, 2018
MSD announced today that the External Data Monitoring Committee has reviewed the results of a key Phase 3 ECHO-301/KEYNOTE-252 study evaluating KEYTRUDA® for the treatment of patients with unresectable or metastatic melanoma by Incyte epacadostat with Mer
Incyte and MacroGenics collaborates for anti-PD-1 monoclonal antibody biospectrumasia
October 27, 2017
Incyte gains exclusive, worldwide development and commercialization rights to MGA012 in all indications
Lilly/Incyte's baricitinib musters mixed data in atopic dermatitis trial fiercebiotech
September 18, 2017
In a phase 2 atopic dermatitis trial, Eli Lilly and Incyte's baricitinib hit its primary endpoint but missed a secondary objective, prompting unfavorable comparisons with Sanofi and Regeneron's recently approved Dupixent.

Previous page 1 2 3 4 5 Next page